收藏切换
Pharmacokinetic Study on Notoginsenoside R1, Ginsenoside Rg1 and Ginsenoside Rb1 of Jingshu Keli in Rat with Cervical Spondylotic Myelopathy Model
收藏切换
Chuanming ZHOU1, 2, Rui CHEN1, 2, Shan XU3, Lihong LYU1, 2, Zhiru XU1, 2, *
Chinese Journal of Pharmaceuticals | 2023, 54(12) : 1745 - 1752
Less
收藏切换
Chinese Journal of Pharmaceuticals | 2023, 54(12): 1745-1752
• Paper •
Pharmacokinetic Study on Notoginsenoside R1, Ginsenoside Rg1 and Ginsenoside Rb1 of Jingshu Keli in Rat with Cervical Spondylotic Myelopathy Model
Full
Chuanming ZHOU1, 2, Rui CHEN1, 2, Shan XU3, Lihong LYU1, 2, Zhiru XU1, 2, *
Affiliations
  • 1.State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 200437
  • 2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai 200437
  • 3.Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008
Published: 2023-12-10 doi: 10.16522/j.cnki.cjph.2023.12.009
Outline
收藏切换

The therapeutic effects of Jingshu Keli(or Jingshu granules) on cervical spondylotic myelopathy(CSM) have been substantiated in clinical practice. Its main active constituents are notoginsenoside R1(1), ginsenoside Rg1(2), and ginsenoside Rb1(3). This study established an ultra-performance liquid chromatography-mass spectrometry(UPLC-MS) method for determination of the concentrations of 1, 2, and 3 in plasma of rats with CSM, then the pharmacokinetic characteristics of 1, 2, and 3 in the rats were investigated. The results showed that after oral gavage administration of Jingshu Keli to the rat, the plasma concentration of 1 was low(<8.892 ng/mL); the cmax, AUC0→t and t1/2 for 2 and 3 were(27.75±4.13) and(123.60±8.56)ng/mL, (255.41±38.59) and(1 344.32±122.52)h·ng·mL–1,(11.97±3.75) and(14.54±2.71)h, respectively. This detection method was sensitive and reliable, and was suitable for the pharmacokinetic study of 1, 2, and 3 in the rat model of CSM.

Jingshu Keli  /  cervical spondylotic myelopathy  /  pharmacokinetics  /  LC-MS/MS
周传铭, 陈瑞, 许杉, 律立红, 徐智儒. 颈舒颗粒中三七皂苷R1、人参皂苷Rg1和人参皂苷Rb1在脊髓型颈椎病模型大鼠中的药代动力学研究. 中国医药工业杂志, 2023 , 54 (12) : 1745 -1752 . DOI: 10.16522/j.cnki.cjph.2023.12.009
Chuanming ZHOU, Rui CHEN, Shan XU, Lihong LYU, Zhiru XU. Pharmacokinetic Study on Notoginsenoside R1, Ginsenoside Rg1 and Ginsenoside Rb1 of Jingshu Keli in Rat with Cervical Spondylotic Myelopathy Model[J]. Chinese Journal of Pharmaceuticals, 2023 , 54 (12) : 1745 -1752 . DOI: 10.16522/j.cnki.cjph.2023.12.009
Year 2023 volume 54 Issue 12
23
7
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2023.12.009
  • Receive Date:2023-01-17
  • Online Date:2026-11-19
  • Published:2023-12-10
Article Data
Affiliations
History
  • Received:2023-01-17
Affiliations
    1.State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 200437
    2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai 200437
    3.Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008
References
Share
https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2023.12.009
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT